BD Shares 510(k) Review Experience With FDA, Urges Others To Do The Same
This article was originally published in The Gray Sheet
Executive SummaryManufacturers should inform FDA about industry experiences with premarket reviews to better identify problems with the process, BD exec Patricia Shrader advocated during a MDUFMA stakeholder meeting in Gaithersburg, Md
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.
Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.